Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CheckVAC: Nivolumab, Ipilimumab, TGFβ-15 Peptide Vaccine, and SBRT in Refractory Pancreatic Cancer
NCT05721846Phase 1Completed
- Start
- May 2023
- Primary completion
- Mar 2026
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IO170 in pancreatic cancer (PC). Primary endpoint: Adverse events at 6 months. Started May 2023; status: completed.
02
Drugs
IO170
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT05721846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05721846.